Significantly reduced incidence and improved survival from prostate cancer over 25 years

被引:3
作者
Serda-Ferrer, Bernat Carles [1 ]
Sanvisens, Arantza [2 ]
Fuentes-Raspall, Rafael [3 ]
Puigdemont, Montse [2 ]
Farre, Xavier [4 ]
Vidal-Vila, Anna [2 ]
Rispau-Pages, Marti [5 ]
Baltasar-Bague, Alicia [1 ]
Marcos-Gragera, Rafael [1 ,2 ]
机构
[1] Univ Girona, Dept Nursing, Girona 17003, Spain
[2] Inst Invest Biomed Girona Dr Josep Trueta IDIBGI, Epidemiol Unit & Girona Cancer Registry, Girona 17004, Spain
[3] Inst Invest Biomed Girona Dr Josep Trueta IDIBGI, Inst Catala Oncol, Radiat Oncol Dept, Girona 17007, Spain
[4] Agencia Salut Publ Catalunya, Dept Hlth, Lleida 25006, Spain
[5] Hosp Univ Dr Josep Trueta, Registre Tumors Hosp RTH ICO ICS, Inst Invest Biomed Girona Dr Josep Trueta IDIBGI, Inst Catala Oncol, Girona 17007, Spain
关键词
Prostate cancer; Incidence; Mortality; Epidemiology; Survival; Temporal trends; METABOLIC SYNDROME; EUROPE; 1999-2007; INCIDENCE RATES; TRENDS; RECOMMENDATION; MORTALITY; DIAGNOSIS; RISK;
D O I
10.1186/s12889-023-17440-7
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundProstate cancer (PCa) was the second most frequent cancer and the fifth leading cause of cancer death among men in 2020. The aim of this study was to analyze trends in the incidence, mortality and survival of PCa in Girona, Spain, over 25 years.MethodsPopulation-based study of PCa collected in the Girona Cancer Registry, 1994-2018. Age-adjusted incidence and mortality rates were calculated per 100,000 men-year. Joinpoint regression models were used for trends, calculating the annual percentage changes (APC). Observed and net survival were analyzed using Kaplan-Meier and Pohar-Perme estimations, respectively.ResultsA total of 9,846 cases of PCa were registered between 1994-2018. The age-adjusted incidence and mortality rates were 154.7 (95%CI: 151.7 157.8) and 38.9 (95%CI: 37.3 -40.6), respectively. An increased incidence of 6.2% was observed from 1994 to 2003 (95%CI: 4.4 -8.1), and a decrease of -2.7% (95%CI: -3.5 -;-1.9) between 2003 and 2018. Mortality APC was -2.6% (95%CI: -3.3 --2.0). Five-year observed and net survival were 72.8% (95%CI: 71.8 - 73.7) and 87.2% (95%CI: 85.9 - 88.4), respectively. Five-year net survival increased over time from 72.9% (1994-1998) to 91.3% (2014-2018).ConclusionsThe analyses show a clear reduction in PCa incidence rates from 2003 on, along with an increase in overall survival when comparing the earlier period with more recent years.
引用
收藏
页数:8
相关论文
共 46 条
  • [1] Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
    Allemani, Claudia
    Matsuda, Tomohiro
    Di Carlo, Veronica
    Harewood, Rhea
    Matz, Melissa
    Niksic, Maja
    Bonaventure, Audrey
    Valkov, Mikhail
    Johnson, Christopher J.
    Esteve, Jacques
    Ogunbiyi, Olufemi J.
    Azevedo e Silva, Gulnar
    Chen, Wan-Qing
    Eser, Sultan
    Engholm, Gerda
    Stiller, Charles A.
    Monnereau, Alain
    Woods, Ryan R.
    Visser, Otto
    Lim, Gek Hsiang
    Aitken, Joanne
    Weir, Hannah K.
    Coleman, Michel P.
    [J]. LANCET, 2018, 391 (10125) : 1023 - 1075
  • [2] Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines?
    Bernal-Soriano, Mari Carmen
    Parker, Lucy Anne
    Lopez-Garrigos, Maite
    Hernandez-Aguado, Ildefonso
    Gomez-Perez, Luis
    Caballero-Romeu, Juan-Pablo
    Pastor-Valero, Maria
    Garcia, Nuria
    Alfayate-Guerra, Rocio
    Lumbreras, Blanca
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (12)
  • [3] European cancer mortality predictions for the year 2020 with a focus on prostate cancer
    Carioli, G.
    Bertuccio, P.
    Boffetta, P.
    Levi, F.
    La Vecchia, C.
    Negri, E.
    Malvezzi, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (05) : 650 - 658
  • [4] Recent trends in prostate cancer in Spain
    Cayuela, L.
    Lendinez-Cano, G.
    Chavez-Conde, M.
    Rodriguez-Dominguez, S.
    Cayuela, A.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2020, 44 (07): : 483 - 488
  • [5] Prostate cancer incidence rates have started to decrease in central Italy
    Crocetti, Emanuele
    Ciatto, Stefano
    Buzzoni, Carlotta
    Zappa, Marco
    [J]. JOURNAL OF MEDICAL SCREENING, 2010, 17 (01) : 50 - 51
  • [6] Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates
    Culp, MaryBeth B.
    Soerjomataram, Isabelle
    Efstathiou, Jason A.
    Bray, Freddie
    Jemal, Ahmedin
    [J]. EUROPEAN UROLOGY, 2020, 77 (01) : 38 - 52
  • [7] Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study
    De Angelis, Roberta
    Sant, Milena
    Coleman, Michel P.
    Francisci, Silvia
    Baili, Paolo
    Pierannunzio, Daniela
    Trama, Annalisa
    Visser, Otto
    Brenner, Hermann
    Ardanaz, Eva
    Bielska-Lasota, Magdalena
    Engholm, Gerda
    Nennecke, Alice
    Siesling, Sabine
    Berrino, Franco
    Capocaccia, Riccardo
    [J]. LANCET ONCOLOGY, 2014, 15 (01) : 23 - 34
  • [8] de Salut D., 2017, Barometre Sanitari de Catalunya, V2017, P1
  • [9] Etxeberria J, 2018, AN SIST SANIT NAVAR, V41, P9, DOI [10.23938/ASSN.0123, 10.23938/assn.0123]
  • [10] Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
    Ferlay, J.
    Colombet, M.
    Soerjomataram, I.
    Dyba, T.
    Randi, G.
    Bettio, M.
    Gavin, A.
    Visser, O.
    Bray, F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 103 : 356 - 387